Lipella Pharmaceuticals Inc. has voluntarily pursued a bankruptcy process in the wake of financial headwinds. The biotechnology company was delisted from the Nasdaq Capital Market in June 2025.
In a recent statement, the Pittsburgh-based company said it plans to pursue a sale of its assets. Operations are expected to continue under court supervision during the Chapter 11 process.
Chapter 11 Filing Details
The company voluntarily filed its petition on March 30, 2026, as per a press release by GlobeNewswire. The case is being handled in the U.S. Bankruptcy Court for the Western District of Pennsylvania.
Court filings state that attorney Michael A. Shiner of Tucker Arensberg, P.C. is offering legal representation to the company.
Lipella Pharmaceuticals Inc. is a clinical-stage biotechnology company; it focuses on drugs that already exist and modifies their active agents for new treatments.
Company Seeks to Sell Assets
Lipella Pharmaceuticals Inc. shared details regarding a plan to sell its assets through the bankruptcy filing. The company plans to use a Section 363 sale process to maximize value for creditors.
According to RK Consultants, the company currently has between one and 49 creditors. Court filings indicate that funds will be available for distribution to the unsecured creditors.
Summarized details from the filing are here:
- Filing Date: March 30, 2026
- Court and Jurisdiction: U.S. Bankruptcy Court for the Western District of Pennsylvania
- Type of Filing: Active, Voluntary Petition
- Chapter: 11
- Case Number: 26-20879
- Estimated Assets:$1,000,001-$10 million
- Estimated Liabilities: $500,001-$1 million
- Reason for Filing: Restructure business under court supervision
Court records further state that the company has total debts of approximately $700 million. The total assets of Lipella Pharmaceuticals Inc. are more than $7 million, the records add.
The company’s list of 20 largest unsecured creditors included Jonathan Kuffman, Doug Johnston, and Sullivan & Worsecster LLP.
A few other documents listed in the petition were a corporate ownership statement and a verification of creditor matrix.
Bankruptcy Follows Nasdaq Delisting
On June 20, 2025, the company announced that the Nasdaq Hearings Panel had delisted its common stock from the Nasdaq Capital Market.
Trading was suspended based on Nasdaq’s finding that certain private placement transactions of the biotechnology company concluded between December 2024 and March 2025 were not in compliance with some of its rules. These included Listing Rules 5100 (Public Interest Concern), 5640 (Voting Rights), and 5635 (Shareholder Approval).
Nasdaq also moved forward with the delisting after the company issued Series C voting convertible shares and warrants to advisors in a manner that did not comply with its rules.
Following the delisting, the company said it plans to continue advancing its drug development programs. A few of these were LP-10 for hemorrhagic cystitis and LP-310 for oral lichen planus.
Ongoing Operations Amid Bankruptcy
The company said that it was pursuing customary first-day motions to continue operations as usual under the court supervision. These motions were related to the maintenance of cash management systems and the payment of employee wages and benefits.
The Chapter 11 filing marks a notable phase for Lipella Pharmaceuticals Inc. as it intends to reorganize its finances and preserve value through the sale of assets. The outcome of the process is expected to be instrumental for the company’s future and potential recovery for creditors.
